CN113272320A - 自杀基因 - Google Patents

自杀基因 Download PDF

Info

Publication number
CN113272320A
CN113272320A CN201980086243.2A CN201980086243A CN113272320A CN 113272320 A CN113272320 A CN 113272320A CN 201980086243 A CN201980086243 A CN 201980086243A CN 113272320 A CN113272320 A CN 113272320A
Authority
CN
China
Prior art keywords
leu
ser
gly
ala
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980086243.2A
Other languages
English (en)
Chinese (zh)
Inventor
K·雷兹瓦尼
E·施帕尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68848450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113272320(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of CN113272320A publication Critical patent/CN113272320A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/25—Suicide switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201980086243.2A 2018-11-19 2019-11-18 自杀基因 Pending CN113272320A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862769405P 2018-11-19 2018-11-19
US62/769,405 2018-11-19
US201862773372P 2018-11-30 2018-11-30
US62/773,372 2018-11-30
US201962791464P 2019-01-11 2019-01-11
US62/791,464 2019-01-11
PCT/US2019/062009 WO2020106619A1 (en) 2018-11-19 2019-11-18 Suicide gene

Publications (1)

Publication Number Publication Date
CN113272320A true CN113272320A (zh) 2021-08-17

Family

ID=68848450

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980086243.2A Pending CN113272320A (zh) 2018-11-19 2019-11-18 自杀基因

Country Status (18)

Country Link
US (1) US20220023343A1 (cg-RX-API-DMAC7.html)
EP (1) EP3883959A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022513099A (cg-RX-API-DMAC7.html)
KR (1) KR20210093977A (cg-RX-API-DMAC7.html)
CN (1) CN113272320A (cg-RX-API-DMAC7.html)
AU (1) AU2019384115A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021009634A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120349A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001300A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007824A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP21044662A (cg-RX-API-DMAC7.html)
IL (1) IL283242A (cg-RX-API-DMAC7.html)
MX (1) MX2021005847A (cg-RX-API-DMAC7.html)
PE (1) PE20211236A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551142A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105238YA (cg-RX-API-DMAC7.html)
TW (1) TW202039538A (cg-RX-API-DMAC7.html)
WO (1) WO2020106619A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7773789B2 (ja) 2020-03-28 2025-11-20 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 癌の治療のための細胞免疫療法
AU2022372894A1 (en) 2021-10-20 2024-04-18 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023177954A1 (en) * 2022-03-18 2023-09-21 University Of Rochester Combination therapy for treatment of cancer, methods and systems of delivery thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000555A2 (en) * 1992-06-25 1994-01-06 Cetus Oncology Corporation Compositions for the inhibition of protein hormone formation and uses thereof
CN1509763A (zh) * 2002-12-20 2004-07-07 �Ϻ�Ψ��������ҩ���޹�˾ 人肿瘤坏死因子-α突变体的应用
CN107106665A (zh) * 2014-06-06 2017-08-29 纪念斯隆-凯特琳癌症中心 靶向间皮素的嵌合抗原受体及其用途
CN107245107A (zh) * 2017-07-18 2017-10-13 深圳市免疫基因治疗研究院 一种基于cd20的嵌合抗原受体及其应用
CN107245106A (zh) * 2017-07-18 2017-10-13 深圳市免疫基因治疗研究院 一种基于cd10的嵌合抗原受体及其应用
CN107312097A (zh) * 2017-07-18 2017-11-03 深圳市免疫基因治疗研究院 一种基于cd30的嵌合抗原受体及其应用
CN107312098A (zh) * 2017-07-18 2017-11-03 深圳市免疫基因治疗研究院 一种基于cd22的嵌合抗原受体及其应用
CN107337737A (zh) * 2017-07-18 2017-11-10 深圳市免疫基因治疗研究院 一种嵌合抗原受体及其应用
CN107365798A (zh) * 2017-07-13 2017-11-21 山东省齐鲁细胞治疗工程技术有限公司 一种携带iCasp9自杀基因的CD19‑CAR‑T细胞及其应用
CN107400168A (zh) * 2017-07-18 2017-11-28 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用
CN108174604A (zh) * 2015-08-07 2018-06-15 西雅图儿童医院(Dba西雅图儿童研究所) 用于实体瘤靶向的双特异性car t细胞

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3817955A1 (de) 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
US6143866A (en) 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
JPWO2005035586A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
AU2011258425B2 (en) * 2010-05-27 2015-12-10 Merck Sharp & Dohme Llc Method for preparing antibodies having improved properties
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
CA2962251A1 (en) * 2014-10-03 2016-04-07 Ntercept, Llc Compositions and methods for inhibiting the biological activity of soluble biomolecules
KR20240024328A (ko) * 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000555A2 (en) * 1992-06-25 1994-01-06 Cetus Oncology Corporation Compositions for the inhibition of protein hormone formation and uses thereof
CN1509763A (zh) * 2002-12-20 2004-07-07 �Ϻ�Ψ��������ҩ���޹�˾ 人肿瘤坏死因子-α突变体的应用
CN107106665A (zh) * 2014-06-06 2017-08-29 纪念斯隆-凯特琳癌症中心 靶向间皮素的嵌合抗原受体及其用途
CN108174604A (zh) * 2015-08-07 2018-06-15 西雅图儿童医院(Dba西雅图儿童研究所) 用于实体瘤靶向的双特异性car t细胞
CN107365798A (zh) * 2017-07-13 2017-11-21 山东省齐鲁细胞治疗工程技术有限公司 一种携带iCasp9自杀基因的CD19‑CAR‑T细胞及其应用
CN107245107A (zh) * 2017-07-18 2017-10-13 深圳市免疫基因治疗研究院 一种基于cd20的嵌合抗原受体及其应用
CN107245106A (zh) * 2017-07-18 2017-10-13 深圳市免疫基因治疗研究院 一种基于cd10的嵌合抗原受体及其应用
CN107312097A (zh) * 2017-07-18 2017-11-03 深圳市免疫基因治疗研究院 一种基于cd30的嵌合抗原受体及其应用
CN107312098A (zh) * 2017-07-18 2017-11-03 深圳市免疫基因治疗研究院 一种基于cd22的嵌合抗原受体及其应用
CN107337737A (zh) * 2017-07-18 2017-11-10 深圳市免疫基因治疗研究院 一种嵌合抗原受体及其应用
CN107400168A (zh) * 2017-07-18 2017-11-28 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CARL PEREZ等: "A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact", CELL, vol. 63, pages 251 - 258 *

Also Published As

Publication number Publication date
WO2020106619A1 (en) 2020-05-28
EP3883959A1 (en) 2021-09-29
CA3120349A1 (en) 2020-05-28
JP2022513099A (ja) 2022-02-07
IL283242A (en) 2021-07-29
CL2021001300A1 (es) 2022-03-18
BR112021009634A2 (pt) 2021-08-10
PE20211236A1 (es) 2021-07-09
TW202039538A (zh) 2020-11-01
PH12021551142A1 (en) 2021-10-25
CO2021007824A2 (es) 2021-06-30
ECSP21044662A (es) 2021-09-30
KR20210093977A (ko) 2021-07-28
MX2021005847A (es) 2021-09-23
AU2019384115A1 (en) 2021-06-17
SG11202105238YA (en) 2021-06-29
US20220023343A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
AU2019315440B2 (en) Improving the efficacy and safety of adoptive cellular therapies
AU2016256582B2 (en) Oncolytic adenovirus encoding a B7 protein
KR102612367B1 (ko) G-단백질 커플화 수용체를 표적화하는 키메라 항원 수용체 및 그의 용도
CN110325205B (zh) T细胞调节性多聚体多肽及其使用方法
US20200338194A1 (en) Chimeric antigen receptor (car) signalling system
KR100895134B1 (ko) 가용성 ctla4 돌연변이 분자 및 그의 용도
CN114585641B (zh) 间皮素car及其用途
US20180044424A1 (en) Car-expressing cells against multiple tumor antigens and uses thereof
KR20180024012A (ko) 종양 표적치료용 인터루킨-15 융합 단백질
CN111093679A (zh) 用于条件调控基因表达的方法和系统
CN111574628A (zh) 靶向bcma的抗体及其应用
KR20190015733A (ko) Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포
HU229680B1 (hu) Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával
CA3006859A1 (en) Group b adenovirus encoding an anti-tcr-complex antibody or fragment
KR20230149327A (ko) 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
JP2024513906A (ja) 人工多能性幹細胞からアルファ-ベータt細胞を生成するための組成物および方法
CN115243713A (zh) 用于递送修饰的淋巴细胞聚集体的方法和组合物
KR20210093977A (ko) 자살 유전자
JP2024513454A (ja) キメラ抗原受容体細胞のための人工細胞死/リポーター系ポリペプチドの組合せおよびその使用
KR20160145789A (ko) 초기 ra를 갖는 대상체에서의 무약물 완화를 달성하기 위한 ctla4 화합물의 용도
CN113150132A (zh) 一种抗SARS-CoV-2的重组抗体及其应用
CN112823166B (zh) 用于修饰的t细胞的条件活性嵌合抗原受体
JP2022510481A (ja) Pdcd-1ホーミングエンドヌクレアーゼバリアント
KR20230002681A (ko) 대형 아데노바이러스 페이로드의 통합
CN120981481A (zh) Cd19特异性抗体构建体以及它们的组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210817

WD01 Invention patent application deemed withdrawn after publication